Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective

Table 2 Type of protein substitute used in each assessment

Forms	L-AAt	CGMP-AAt
Forms	L-AAt	L-AA	CGMP-AA
Powders	PKU 3 Advanta® (Nutricia) (n = 4)	PKU 3 Advanta® (Nutricia) (n = 2)	Glytactin BetterMilk® (Cambrooke) (n = 9)
	PhenylAde® (Taranis) (n = 2)
	PKU 2 Secunda® (Nutricia) (n = 1)
	PKU Anamix Junior® (Nutricia) (n = 1)
	Phlexy 10 Drink Mix® (Nutricia) (n = 1)
Liquids	PKU Cooler 10, 15 and 20® (Vitaflo) (n = 9) XPhe Jump 10® (MetaX) (n = 1)	PKU Cooler 10, 15 and 20® (Vitaflo) (n = 5) PKU Lophlex LQ 10® (Nutricia) (n = 1)	Glytactin RTD 15® (Cambrooke) (n = 2) Glytactin RTD 10® (Cambrooke) (n = 3)
Bars	PhenylAde Amino Acid Bar® (Taranis) (n = 1)

CGMP-AA, casein glycomacropeptide supplements; L-AA, phenylalanine-free L-amino acid supplements; PKU, phenylketonuria; RTD, ready to drink; L-AAt, type of protein substitute when taking L-AA; CGMP-AAt, type of protein substitute when taking CGMP-AA

ISSN: 1750-1172